NAV
₹22.3920
as of 29 Sept 2026
Expense Ratio
1.03%
Lumpsum returns (CAGR)
- 1Y
- +30.35%
- 3Y
- —
- 5Y
- —
- Since Inception
- +30.98%
SIP returns (XIRR)
- 1Y
- +35.51%
- 3Y
- —
- 5Y
- —
- Since Inception
- +26.38%
Performance Comparison
Sectoral allocation
as of 31 Aug 2026Each sector links to the mutual funds most exposed to it.
Thinking about HDFC Pharma and Healthcare Fund · Direct · Growth?
Talk to our AMFI-registered team — free, no pressure. We'll help you see if this fund fits your goals.
Compare with Similar Funds
Fund Details
Available transactions
Portfolio holdings
portfolio shared with HDFC Pharma and Healthcare Fund - Growth Option
- 1Divis Laboratories Ltd.9.54%
- 2Sun Pharmaceutical Industries Ltd.8.94%
- 3Torrent Pharmaceuticals Ltd.4.08%
- 4Max Healthcare Institute Limited4.06%
- 5Lupin Ltd.4.04%
- 6Cipla Ltd.3.94%
- 7Aster Dm Quality Care Limited3.84%
- 8Neuland Laboratories Limited3.70%
- 9Anthem Biosciences Limited3.48%
- 10Acutaas Chemicals Limited3.24%
What this fund does
HDFC Pharma and Healthcare Fund · Direct · Growth invests in stocks from a specific sector or theme, offering concentrated exposure to a particular area of the economy. These funds carry sector-specific risks but can deliver significant returns when the underlying sector performs well.
About This Fund
HDFC Pharma and Healthcare Fund · Direct · Growth is a Sectoral / Thematic mutual fund offered by HDFC Mutual Fund. The fund has been operational for over 2 years. The current expense ratio is 1.03%.